Polyomavirus, discovered by Ludwik Gross as a contaminant in a murine leukemia virus preparation in the early 1950s, was termed polyomavirus by Sarah Stewart and Bernice Eddy because of its ability to elicit multiple different types of tumors in mice. By 1960, culture conditions for growing polyomavirus in vitro had been developed, and its ability to "transform" cells in culture had been established. Because of the ease of propagation and the small size of its double-stranded DNA genome (<5 kb), polyomavirus quickly became one of the favorite model systems for studying the process of carcinogenesis. The hope was that an understanding of how this simple tumor virus transforms cells would shed light on the mechanisms underlying the human disease. The isolation of temperature-sensitive polyomavirus mutants defective in transformation at the restrictive temperature and the identification of viral transcripts in transformed cells suggested that a viral gene product might be responsible for the transformed state. In addition, rodents infected with polyomavirus had been found to develop antibodies against polyomavirus-infected cell-specific antigens, which became known as T (tumor) antigens. Although formal proof that the T antigens are encoded by the polyomavirus genome had to wait several more years, at the time it seemed plausible that these proteins were indeed virally coded and that one or more of them had oncogenic properties. When the work that ultimately led to our paper began in 1977, there was intense interest in the identity of the polyomavirus T antigen proteins and the molecular basis for their ability to transform cells.
From the early days, the Saik Institute had been a mecca for the study of polyomavirus because Renato Dulbecco, a founding faculty member of the Institute in 1964, had been one of the pioneers in studying polyomavirus and had trained a cadre of young investigators who went on to study polyomavirus in their own groups--these included Mike Fried who moved to ICRF in London, Tom Benjamin who moved to Harvard Medical School, and Walter Eckhart who stayed at the Salk Institute to set up his own group studying polyomavirus. During 1977 and early 1978, we, together with Mary Anne Hutchinson, had been busy characterizing the polyomavirus T antigens by peptide mapping of immunoprecipitated metabolically labeled proteins, combined with analysis of virus deletion mutants and in vitro translation of virally derived mRNAs and cRNAs. For polyomavirus, three different sized T antigens had been identified by Yoshi Ito and Renato Dulbecco, who had moved to ICRF in 1972 (Ito et al., 1977a (Ito et al., , 1977b . These became known rather unimaginatively as large, middle, *Correspondence: hunter@salk.edu and small T antigens. We Hunter et al., 1978) , at the same time as John Smart and Yoshi Ito (Smart and Ito, 1978) , found that the three T antigens had a common N-terminal region but also each had unique peptides, suggesting an unusual structural relationship. With the completion of the nucleotide sequence of the polyomavirus genome by our collaborators, Prescott Deininger and Ted Friedmann at UCSD, we were able to prove that all three T antigens are indeed virally encoded and also to define the coding regions for the three T antigens . We found that the C terminus of the middle T antigen is translated from the same sequence as part of the large T antigen, but in a different reading frame, and that the very C terminus of small T antigen is derived from the third reading frame. At about this time, the first evidence for splicing of adenovirus and SV40 mRNAs was emerging, and in due course it was found that the mRNAs for the large, middle, and small T antigens are derived by different alternative splicing events from a single precursor RNA transcribed from the so-called early region of the viral genome--a prime example of how genetic information is compacted into a small genome.
Genetic analyses indicated that the large and middle T antigens had distinct functions in cell transformation and that the large T antigen was required for viral DNA replication, but the biochemical functions of the proteins were not known. Moreover, in contrast to the v-src oncogene of the RNA tumor virus, Rous sarcoma virus (RSV), the transforming region of the polyomavirus genome was not recognizably of cellular origin, nor were any of the three polyomavirus T antigens related in sequence to proteins of known function. Nevertheless, the middle T antigen was of particular interest because another small DNA tumor virus, simian virus 40, although similar in size and in overall genetic organization, does not encode a middle T antigen, and evidence was emerging that middle T antigen itself is required for transformation. The next question was how does middle T transform cells.
In thinking about how polyomavirus T antigens might transform cells, we were prompted to look for protein kinase activity associated with the T antigens because of the discovery, made independently by the Erikson and Bishop/Varmus groups, that p60 vs~ (v-Src), the protein encoded by the RSV v-src gene, had an associated protein kinase activity (Collett and Erikson, 1978; Levinson et al., 1978) . This kinase activity could be detected as result of phosphorylation of the antibody heavy chain or v-Src itself, when immunoprecipitates containing v-Src were incubated in kinase buffer with ~-32P-labeled ATP, a protocol that became known as the immune complex kinase assay. This result electrified the cancer research community because protein phosphorylation was a well-established principle for reversible regulation of protein activity, and it immediately suggested that v-Src transformed cells through phosphorylation of a set of target proteins, thus altering their activity. Moreover, Hartmut Beug and Thomas Graf had just shown that cytoplasts made from chick cells transformed with a ts (Beug et al., 1978) , suggesting that this aspect of the transformed phenotype is itself reversible and is therefore mediated by a reversible process such as protein phosphorylation. We were intrigued by the notion that there might be a universal principle of transformation and that other tumor viruses, including DNA tumor viruses like polyomavirus, use phosphorylation as a mechanism of transformation. We quickly set out to test whether polyomavirus T antigens might have an associated protein kinase activity. Using immune complex kinase assays, we found that immunoprecipitates of polyomavirus T antigens from infected cells indeed did contain a protein kinase activity that in this case resulted in the phosphorylation of the middle T antigen . This protein kinase activity was absent from precipitates containing only large and small T antigens or that had nontransforming mutant middle T antigen, thus correlating with transforming function and implying that the activity was somehow dependent on middle T antigen itself.
At the XLIV Cold Spring Harbor Symposium, held May 31-June 5, 1979, we learned that two other groups, Alan Smith, Mike Fried, and Beverly Griffin at the ICRF in London and Brian Schaffhausen and Tom Benjamin at Harvard Medical School, had also detected kinase activity associated with the polyomavirus middle T antigen. We all agreed to submit our papers descd6ing these findings as soon as possible to Cell, with the hope that they would be published back to back. In the rush to get our paper submitted, we did not carry out the conventional analysis to determine whether middle T antigen becomes phosphorylated on serine or threonine, which at the time were the only known phosphoryiated amino acids in proteins. But we assumed this was simply a formality that could be done while the paper was being revised (indeed one of the reviewers requested these data!). Our paper was submitted to Cell on June 13,1979.
On June 12, Tony Hunter set up the first experiment to determine the identity of the phosphorylated amino acid in polyomavirus middle T antigen. He isolated 32p_ labeled middle T protein, phosphorylated in an immunoprecipitate, and separated the amino acids released by acid hydrolysis on a cellulose thin layer plate by electrophoresis, using a homemade water-cooled flat bed apparatus and a lab stock of pH 1.9 buffer that had already been used several times before. Following autoradiography, he found a radioactive spot running between the stained phosphoserine (P.Ser) and phosphothreonine (P.Thr) markers, but to his surprise it did not comigrate with either of them (as he recorded rather laconically in his experimental notes "spot does not coincide with P.Ser and P.Thr internal markers") ( Figure 1 ). After repeating the experiment to make sure that the result was not an artifact, he speculated that the phosphorylated amino acid might be tyrosine since tyrosine was the only other hydroxyamino acid in proteins, and, like serine and threonine, it would be expected to generate an acidstable phosphate ester if phosphorylated.
Tyrosine phosphorylation of proteins, however, had never been reported, and no phosphotyrosine (P.Tyr) marker was available. Without realizing that a chemical synthesis for P.Tyr had been devised in 1941 (Plimmer, 1941) , Tony made a small quantity of P.Tyr by the decidedly suboptimal method of mixing POCI3 with tyrosine in aqueous solution. Initial experiments showed that the ~2P-labeled compound comigrated with chemically synthesized P.Tyr upon one-dimensional separation at pH 1.9. To be certain of the identification, Tony devised a two-dimensional separation system using pH 1.9 electrophoresis followed by chromatography in the second dimension and used this to confirm that acid hydrolysates of 32P-labeled polyomavirus middle T antigen contained a phosphoamino acid that comigrated with the synthetic P.Tyr marker in both dimensions.
Although by this time we were reasonably convinced that middle T antigen was being phosphorylated on tyrosine in vitro, because tyrosine phosphorylation was unprecedented, we were unsure whether this was a genuine end-state posttranslational modification or whether it might represent an unusually stable phosphoenzyme intermediate. We were aware that the VPg protein of poliovirus is linked to the virion RNA through a phosphate ester bond between a tyrosine in VPg and the 5' uridylic acid residue of the RNA (Ambros and Baltimore, 1978; Rothberg et al.,. 1978 ), but we could not find any reports of a protein kinase activity that phosphorylated tyrosine, and this was confirmed by discussions with Ed Krebs, Gordon Gill, and several other protein phosphorylation mavens.
Because we had some remaining concern that P.Tyr might possibly be generated from 3=P-labeled middle T antigen by an acid-catalyzed reaction during acid hydrolysis, rather than as a result of phosphorylation by a tyrosine-specific protein kinase, Tony tested whether P.Tyr could be released from 32p-labeled middle T antigen by complete proteolysis as well as by acid hydrolysis. During this time, he had been collaborating with our Tumor Virology Laboratory colleagues, Karen Beemon and Bart Seffon, to characterize the v-Src protein kinase activity, and this enabled him to use 32P-labeled immunoglobulin heavy chain phosphorylated by v-Src in an immunoprecipitate from RSV-transformed cells as one of the acid hydrolysis controls. This was expected to yield P.Thr, based on the report from Marc Collett and Ray Erikson that v-Src phosphorylates threonine in the heavy chain (Collett and Erikson, 1978) . Much to his surprise, Tony found that the only phosphorylated amino acid released was P.Tyr, which he confirmed by two-dimensional separation (P.Tyr and P.Thr migrate together using the conventional technique of paper electrophoresis at pH 1.9, which accounts for the original conclusion).
Deciding to repeat the v-Src experiments to generate publication data, Tony made up fresh pH 1.9 electrophoresis buffer and found to his chagrin that synthetic P.Tyr and P.Thr now comigrated. He speculated that the "old" buffer must have changed in some way to allow resolution of P.Tyr and P.Thr. It turned out that the pH of the buffer had dropped from 1.9 to 1.7 with repeated use. in retrospect, his use of the "old" buffer was a crucial part of the whole discovery. For a time, we had to use deliberately "aged" buffer in our experiments to separate P.Tyr and P.Thr. Based on a suggestion by our colleague Jack Rose, who was familiar with how the VPg tyrosine phosphate diester linkage had been characterized (Ambros and Baltimore, 1978; Rothberg et al., 1978) , Tony and Bart Sefton subsequently developed an improved two-dimensional separation for the three phosphoamino acids, using electrophoresis at pH 1.9 followed by electrophoresis at pH 3.5, a method that is still in use today.
Tony and Bart Sefton then set out to determine whether tyrosine phosphorylation actually occurs in vivo. They found that v-Src, isolated from 32P-labeled RSV-transformed chick embryo fibroblasts, contained both P.Tyr and P.Thr and that a cellular protein that coprecipitated with v-Src also contained P.Tyr. Furthermore, they observed an approximately 10-fold increase in the level of P.Tyr in total proteins in RSV-transformed chick cells compared to untransformed cells, strongly implying that v-Src acts as a protein-tyrosine kinase in vivo. In cells transformed by a ts mutant of RSV, they found that P.Tyr levels were elevated at the permissive temperature, when cells were transformed, and were low in the untransformed cells at the restrictive temperature . Moreover, the level of P.Tyr fell within 30 min of shifting cells from the permissive to the restrictive temperature, implying the existence of protein-tyrosine phosphatases that could rapidly dephosphorylate proteins phosphorylated by v-Src. Ironically, polyomavirus-transformed cells did not contain elevated levels of P.Tyr in proteins . Subsequently, Sara Courtneidge and Alan Smith showed that the tyrosine kinase activity in middle T antigen immunoprecipitates is not intrinsic to middle T, but rather due to association with c-Src (Courtneidge and Smith, 1983) . Middle T antigen itself and signaling proteins downstream of the middle T antigen/c-Src complex can be shown to contain P.Tyr in polyomavirus transformed cells, but the total activity of activated c-Src in polyomavirus-transformed cells is much lower than that of v-Src in RSV-transformed cells, explaining the failure to find increases in P.Tyr in whole-cell protein analysis. The fact that the tyrosine kinase activity of temperaturesensitive mutant v-Src was temperature sensitive in vitro strongly implied that this activity was an intrinsic property of v-Src, but it was not until the protein sequence of the catalytic subunit of the cAMP-dependent protein kinase was reported revealing a close relationship to the C-terminal half of the predicted v-Src sequence that this was formally established (Barker and Dayhoff, 1982) .
By the time we were ready to submit our revised manuscript on the phosphorylation of polyomavirus T antigens in the fall of 1979, we were convinced that tyrosine phosphorylation was real and important. We revised the manuscript to include the identification of tyrosine as the phosphorylated amino acid, changing the title to emphasize that observation, and the paper was resubmitted on September 21. The paper was published in Cell in December, 1979, together with those of the Schaffhausen/Benjamin (Schaffhausen, and Benjamin, 1979) and Smith/Griffin/Fried (Smith et al., 1979) groups, which described similar findings, but without identification of phosphoryiated tyrosine in middle T antigen.
The initial response to our discovery of protein-tyrosine kinase activity in polyomavirus T antigen immunoprecipitates was muted. It was not until a few months later, in the spring of 1980, when observations of tyrosine phosphorylaUon by retroviral transforming proteins were published, that the significance of the discovery began to be widely appreciated. At the same time that Tony and Bart reported their findings on v-Src and c-Src tyrosine phosphorylation in vitro and in vivo , Owen Witte, Asim Dasgupta, and David Baltimore at MIT reported that v-Abl was phosphorylated on tyrosine in vitro ( (Witte et al., 1980) . Although they concluded that the P.Tyr in v-Abl was likely to reflect the formation of a phosphoenzyme intermediate, their finding of P.Tyr reinforced the observations made on Src. Subsequent work by Marc Collett, Tony Purchio, and Ray Erikson showed that purified v-Src can phosphorylate a number of nonphysiological substrates on tyrosine, reinforcing the notion that v-Src is a true prootein-tyrosine kinase (Collett et al., 1980) . Even though tyrosine phosphorylation was an unprecedented process, there was almost no opposition to the idea that this is a genuine physiological process, and it was quickly adopted by the research community. In 1978, Stanley Cohen at Vanderbilt had reported that the EGF receptor was an EGF-stimulated protein-threonine kinase (Carpenter et al., 1978) . Once he learned that P.Thr and P.Tyr are not resolved by electrophoresis at pH 1.9, he and Hiroshi Ushiro re-examined the amino acid specificity of the EGF receptor kinase and found that it too phosphorylated tyrosine (Ushiro and Cohen, 1980) . This finding provided a link between the EGF receptor and retroviral oncoproteins like v-Src and v-Abl and suggested that neoplastic cell transformation by viral protein-tyrosine kinases might involve activation of signaling pathways stimulated by growth factor receptors.
It seems clear now that cell transformation by v-Src results from the phosphorylation of cellular proteins on tyrosine. Although numerous substrates have been identified, including proteins that are also targets of growth factor receptor protein-tyrosine kinases, exactly which substrates are crucial for the transforming activity of v-Src remains an enigma. In contrast, cell transformation by the polyomavirus middle T antigen appears to result from the activation of growth signaling pathways by a middle T/c-Src complex. The c-Src protein kinase activity phosphorylates tyrosines in middle T antigen, which, in turn, act as binding sites for adaptor molecules or downstream signaling effectors, including Shc, which activates the Ras/ERK MAP kinase pathway, and phosphatidylinositol-3' kinase.
Our discovery of tyrosine phosphorylation during our studies of polyomavirus T antigens was made possible by several fortunate circumstances. One was the dedication and technical expertise of Mary Anne Hutchinson, who refined the immunoprecipitation, immune complex kinase assays, and electrophoretic separations that facilitated all our experiments. Another was the interactive environment created by our colleagues in the Tumor Virology Laboratory at the Salk Institute, who helped us through many stimulating discussions and collaborations. Additionally--and not least--was the accidental discovery that "aged" pH 1.9 electrophoresis buffer allowed the separation of P.Tyr and P.Thr. In retrospect, it was a lot of fun.
Initially, we did not foresee that tyrosine phosphorylation would be such an important signaling mechanism or the underlying cause for many types of human cancer. When we told our story to Renato Dulbecco in September 1979, he immediately suggested that tyrosine phosphorylation might be a common basis for cell transformation. His instinct was rapidly vindicated. By the end of 1980, we knew of four tyrosine kinases, three retroviral transforming proteins, v-Src, v-Abl, and v-Fes, in addition to the EGF receptor, and by 1982, the insulin receptor and the PDGF receptor had been added to the list. Twenty years later, as a result of the completion of the human genome sequence, we now know that the human genome encodes 90 distinct tyrosine kinases. The early hints in 1979 that aberrant tyrosine phosphorylation might play a role in human disease have been borne out, and more than half of the 90 human tyrosine kinases have been implicated in the genesis of at least one type of cancer (Blume-Jensen and Hunter, 2001) . Gratifyingly, Gleevec TM, the first drug that acts as a tyrosine kinase inhibitor ('I'KI) was approved by the FDA in 2001 for cancer therapy, and it is proving a very effective treatment for early stage chronic myelogenous leukemia, a disease driven by Bcr-Abl, an activated form of the Abl tyrosine kinase, as well as for gastrointestinal stromal tumors, where an activated mutant form of the c-Kit stem cell factor receptor or the PDGF receptor is responsible. A second TKI, Iressa TM, an EGF receptor inhibitor, has also recently been approved for cancer therapy. These TKIs are the harbingers of what will surely became a major new class of cancer drugs. 
